Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pasi Antero Janne, M.D.,PH.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Identifying Novel Oncogenes in Non Small Cell Lung Cancer of Young Patients
Summer, 06/24/13 - 08/09/13

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R35CA220497 (JANNE, PASI A) Sep 10, 2018 - Aug 31, 2025
    NIH/NCI
    Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
    Role: Principal Investigator
  2. R01CA222823 (JANNE, PASI A) Feb 1, 2018 - Jan 31, 2023
    NIH/NCI
    Resistance and Sensitivity to MET Inhibitors in Lung Cancer
    Role: Principal Investigator
  3. R01CA172592 (JANNE, PASI A) Sep 1, 2013 - Jun 30, 2018
    NIH/NCI
    Targeting RET in Lung Cancer
    Role: Principal Investigator
  4. P01CA154303 (MEYERSON, MATTHEW L.) May 11, 2012 - Aug 31, 2022
    NIH/NCI
    Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
    Role: Co-Principal Investigator
  5. U01HG006492 (GARRAWAY, LEVI A.) Feb 10, 2012 - Nov 30, 2016
    NIH/NHGRI
    The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodríguez ML, Gandhi R, Lafuente-Sanchis A, Aupí M, Alcácer Fernández-Coronado J, Martín-Martorell P, Cremades A, Galbis-Caravajal JM, Alcácer J, Christensen CL, Simms P, Hess A, Asahina H, Kahle MP, Al-Shahrour F, Borgia JA, Lahoz A, Insa A, Juan O, Janne PA, Wong KK, Carretero J, Shimamura T. CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC. Cancer Res. 2019 Jul 04. PMID: 31273063.
    Citations:    
  2. To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 Jul; 9(7):926-943. PMID: 31092401.
    Citations:    
  3. Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, Riely GJ, Aravanis A, Oxnard GR. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann Oncol. 2019 Apr 01; 30(4):597-603. PMID: 30891595.
    Citations:    
  4. Harris EJ, Hanna GJ, Chau N, Rabinowits G, Haddad R, Margalit DN, Schoenfeld J, Tishler RB, Barletta JA, Nehs M, Janne P, Huang J, Groden P, Kacew A, Lorch J. Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106. PMID: 30863722.
    Citations:    
  5. Gill RR, Murphy DJ, Kravets S, Sholl LM, Janne PA, Johnson BE. Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy. J Surg Oncol. 2018 Dec; 118(7):1170-1177. PMID: 30261097.
    Citations:    Fields:    Translation:Humans
  6. Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni M, Badalucco L, Fitzpatrick E, Kao HF, Kuraguchi M, Bittinger M, Kirschmeier PT, Gray NS, Barbie DA, Jänne PA. A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunol Res. 2018 12; 6(12):1511-1523. PMID: 30242021.
    Citations:    Fields:    
  7. Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 Dec 01; 24(23):5963-5976. PMID: 30072474.
    Citations:    Fields:    
  8. Powell CE, Gao Y, Tan L, Donovan KA, Nowak RP, Loehr A, Bahcall M, Fischer ES, Jänne PA, George RE, Gray NS. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2018 05 10; 61(9):4249-4255. PMID: 29660984.
    Citations: 1     Fields:    
  9. Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018 Sep 15; 24(18):4437-4443. PMID: 29567812.
    Citations: 1     Fields:    
  10. Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553. PMID: 29301825.
    Citations: 1     Fields:    
  11. Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 10 31; 6. PMID: 29087937.
    Citations:    Fields:    
  12. Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM. Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 Oct 01; 23(19):5737-5744. PMID: 28679767.
    Citations: 4     Fields:    Translation:Humans
  13. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 05 15; 77(10):2712-2721. PMID: 28363995.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  14. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912.
    Citations: 19     Fields:    Translation:Humans
  15. Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 02 01; 6. PMID: 28145866.
    Citations: 11     Fields:    Translation:HumansCells
  16. Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, Thomas T, Janne PA, Garraway LA, Carter SL, Beroukhim R, Lorch JH, Van Allen EM. Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. Clin Cancer Res. 2017 May 01; 23(9):2367-2373. PMID: 27797976.
    Citations: 4     Fields:    Translation:HumansCells
  17. Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, Garber J, Joffe S, Lindeman N, Wagle N, Garraway LA, Van Allen EM. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79. PMID: 27460824.
    Citations: 15     Fields:    Translation:Humans
  18. Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet. 2016 07 07; 99(1):246. PMID: 27392080.
    Citations: 6     Fields:    
  19. Green RC, Goddard KAB, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet. 2016 06 02; 98(6):1051-1066. PMID: 27181682.
    Citations: 27     Fields:    Translation:Humans
  20. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501. PMID: 26883990.
    Citations: 153     Fields:    Translation:HumansAnimals
  21. Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct; 33(5):1108-14. PMID: 26123926.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  22. Sholl LM, Nishino M, Pokharel S, Mino-Kenudson M, French CA, Janne PA, Lathan C. Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. J Thorac Oncol. 2015 Jun; 10(6):951-9. PMID: 26001144.
    Citations: 6     Fields:    Translation:Humans
  23. Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63. PMID: 26014096.
    Citations: 12     Fields:    Translation:HumansCells
  24. Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK, Hammerman PS. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015 Apr 23; 34(17):2167-77. PMID: 24909170.
    Citations: 9     Fields:    Translation:HumansCells
  25. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, Lawrence M, Lichtenstein LT, Gentry JG, Huang FW, Fostel J, Farlow D, Barbie D, Gandhi L, Lander ES, Gray SW, Joffe S, Janne P, Garber J, MacConaill L, Lindeman N, Rollins B, Kantoff P, Fisher SA, Gabriel S, Getz G, Garraway LA. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8. PMID: 24836576.
    Citations: 137     Fields:    Translation:HumansCells
  26. Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel JB, Janne PA, Sharpless NE, Engelman JA, Shapiro GI, Kung AL, Wong KK. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res. 2014 Mar 01; 20(5):1204-1211. PMID: 24327273.
    Citations: 14     Fields:    Translation:HumansAnimals
  27. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec; 3(12):1355-63. PMID: 24078774.
    Citations: 242     Fields:    Translation:HumansAnimalsCells
  28. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013 Aug; 3(8):870-9. PMID: 23715154.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  29. Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013 Apr 15; 73(8):2574-86. PMID: 23436801.
    Citations: 38     Fields:    Translation:HumansAnimalsCells
  30. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013 Jan; 14(1):38-47. PMID: 23200175.
    Citations: 196     Fields:    Translation:HumansCTClinical Trials
  31. Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. Biosci Rep. 2012 Aug; 32(4):413-22. PMID: 22668349.
    Citations: 10     Fields:    Translation:HumansCells
  32. Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 2012 Jun 10; 30(17):2063-9. PMID: 22547605.
    Citations: 80     Fields:    Translation:HumansCTClinical Trials
  33. Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Janne PA, Nakagawa K. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. Br J Cancer. 2012 Feb 14; 106(4):763-7. PMID: 22240786.
    Citations: 15     Fields:    Translation:HumansCells
  34. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109. PMID: 22147736.
    Citations: 29     Fields:    Translation:HumansPHPublic Health
  35. Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res. 2012 Jan 15; 18(2):380-91. PMID: 22090358.
    Citations: 18     Fields:    Translation:HumansCells
  36. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89. PMID: 22328973.
    Citations: 166     Fields:    Translation:HumansAnimalsCells
  37. Berlin J, Keedy VL, Janne PA, Yee L, Rizvi NA, Jin X, Copigneaux C, Hettmann T, Beaupre DM, LoRusso P. A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3026. PMID: 28022683.
    Citations:    
  38. Ramalingam SS, Spigel DR, Steins M, Engelman JA, Schneider C, Novello S, Eberhardt WE, Crino L, Janne PA, Liu L, Brownstein CM, Reck M. Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 May 20; 29(15_suppl):7527. PMID: 28023261.
    Citations:    
  39. Crinò L, Kim D, Riely GJ, Janne PA, Blackhall FH, Camidge DR, Hirsh V, Mok T, Solomon BJ, Park K, Gadgeel SM, Martins R, Han J, De Pas TM, Bottomley A, Polli A, Petersen J, Tassell VR, Shaw AT. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011 May 20; 29(15_suppl):7514. PMID: 28023275.
    Citations:    
  40. Pennell NA, Neal JW, Govindan R, Janne PA, Evans TL, Costa DB, Rosovsky RP, Lanuti M, Azzoli CG, Sequist LV. The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS209. PMID: 28023496.
    Citations:    
  41. Ortiz TM, Joshi VA, Heon S, Butaney M, Chen L, Jackman DM, Kwiatkowski DJ, Lindeman NI, Janne PA, Johnson BE. The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). J Clin Oncol. 2011 May 20; 29(15_suppl):7517. PMID: 28023283.
    Citations:    
  42. Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011 Mar 01; 17(5):1131-9. PMID: 21220471.
    Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
  43. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, Adamia S, Wu C, Gray N, Griffin JD. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010 May 27; 115(21):4206-16. PMID: 20299508.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  44. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. PMID: 20164920.
    Citations: 1134     Fields:    Translation:HumansCells
  45. Qin W, Kozlowski P, Taillon BE, Bouffard P, Holmes AJ, Janne P, Camposano S, Thiele E, Franz D, Kwiatkowski DJ. Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. Hum Genet. 2010 Mar; 127(5):573-82. PMID: 20165957.
    Citations: 20     Fields:    Translation:Humans
  46. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23. PMID: 19671850.
    Citations: 173     Fields:    Translation:Humans
  47. Janne PA, Reckamp K, Koczywas M, Engelman JA, Camidge DR, Rajan A, Khuri F, Liang JQ, O'Connell J, Giaccone G. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol. 2009 May 20; 27(15_suppl):8063. PMID: 27962636.
    Citations:    
  48. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol. 2009 May 20; 27(15_suppl):8065. PMID: 27962638.
    Citations:    
  49. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12. PMID: 18520291.
    Citations: 2     Fields:    Translation:Humans
  50. Kuang Y, Rogers A, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel R, Janne PA. Non-invasive detection of EGFR T790M in gefitinib/erlotinib resistant NSCLC. J Clin Oncol. 2008 May 20; 26(15_suppl):8075. PMID: 27948977.
    Citations:    
  51. Janne PA, Schellens JH, Engelman JA, Eckhardt SG, Millham R, Denis LJ, Britten CD, Wong SG, Boss DS, Camidge DR. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol. 2008 May 20; 26(15_suppl):8027. PMID: 27949038.
    Citations:    
  52. Jackman DM, Sequist LV, Cioffredi L, Ruiz MG, Janne PA, Giaccone G, Miller VA, Johnson BE. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8035. PMID: 27949020.
    Citations:    
  53. Finocchiaro G, Cappuzzo F, Rossi E, Toschi L, Janne PA, Roncalli M, Ligorio C, Rimassa L, Santoro A, Varella-Garcia M. Insuline like growth factor receptor-1 (IGFR-1), MET, and BRAF and primary resistance to cetuximab therapy in colorectal cancer patients. J Clin Oncol. 2008 May 20; 26(15_suppl):4135. PMID: 27950941.
    Citations:    
  54. Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71. PMID: 18349397.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  55. Jänne, PA. Malignant Mesothelioma. Harrison's Manual of Oncology, Chabner, BA, Lynch, TJ Jr., Longo, DL (eds). 2008; 445-454.
  56. Jänne, P.A., Simon, G.R., Langer, C.J., Taub, R.N., Dowlati, A., Fidias, P., Monberg, M., Obasaju, C., and Kindler, H.L. . A Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naïve Malignant Pleural Mesothelioma. Journal of CLinical Oncology. 2008.
  57. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., Joshi V.A., McCollum D., Evans T., Muzikansky A., Kuhlman G., Goldberg J.S., Patel J., Malamud S., Settleman J., Iafrate A.J., Engelman J.A., Haber D.A., Johnson B.E., and Lynch T.J. . First-line gefitinib in advanced non-small-cell lung cancer patients harboring somatic EGFR mutations. Journal of Clinical Oncology. 2008.
  58. Jackman, D.M., Kindler, H.L, Yeap, B.Y., Fidias, P., Salgia, R., Lucca, J., Morse, L.K., Oster, P.A., Johnson, B.E., and Jänne, P.A . Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008.
  59. Ahn, M.-J., Park, B.-B., Ahn, J.S., Kim, S.W., Kim, H.-T., Lee, J.S., Kang, J.H., Cho, J.Y., Song, H.S., Park, S.H., Sohn, C.H., Shin, S.W., Choi, J.H., Ki, C.-S., Park, C.K., Holmes, A.J., Jänne, P.A., and Park. K. . Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer ?. Clinical Cancer Research. 2008.
  60. Engelman, J.A., and Jänne, P.A. . Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clinical Cancer Research. 2008.
  61. Simon, G.R., Verschraegen, C.F., Jänne, P.A., Langer, C.J., Dowlati, A., Gadgeer, S.M., Kalley, K., Kalemkarian, G., Traynor, A.M., Peng, G., Gill, J., Obasaju, C.K. and Kindler, H.L. Pemetrexed plus Gemcitabine as Front-Line Chemotherapy for Patients with Peritoneal Mesothelioma: Final Report of a Phase II Trial. Journal of Clinical Oncology. 2008.
  62. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007 Dec 15; 67(24):11924-32. PMID: 18089823.
    Citations: 194     Fields:    Translation:HumansAnimalsCells
  63. Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008 Apr; 19(4):717-23. PMID: 17974556.
    Citations: 76     Fields:    Translation:Humans
  64. Jänne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44. PMID: 17761977.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  65. Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA. Ras pathway activation in malignant mesothelioma. J Thorac Oncol. 2007 Sep; 2(9):789-95. PMID: 17805054.
    Citations: 12     Fields:    Translation:HumansCells
  66. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Jänne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16; 448(7155):807-10. PMID: 17676035.
    Citations: 354     Fields:    Translation:HumansAnimalsCells
  67. Allen AM, Den R, Wong JS, Zurakowski D, Soto R, Jänne PA, Zellos L, Bueno R, Sugarbaker DJ, Baldini EH. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1366-74. PMID: 17674974.
    Citations: 10     Fields:    Translation:Humans
  68. Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):917-20. PMID: 17625975.
    Citations: 9     Fields:    Translation:Humans
  69. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jänne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007 Jul; 12(1):81-93. PMID: 17613438.
    Citations: 83     Fields:    Translation:AnimalsCells
  70. Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol. 2007 Jun 01; 25(16):2248-55. PMID: 17538169.
    Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
  71. Li J, Berbeco R, Distel RJ, Jänne PA, Wang L, Makrigiorgos GM. s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. Nucleic Acids Res. 2007; 35(12):e84. PMID: 17545195.
    Citations: 8     Fields:    Translation:HumansCells
  72. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jänne PA, Johnson BE, Chin L, Wong KK. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15; 67(10):4933-9. PMID: 17510423.
    Citations: 70     Fields:    Translation:AnimalsCells
  73. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43. PMID: 17463250.
    Citations: 1447     Fields:    Translation:HumansAnimalsCells
  74. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6. PMID: 17228019.
    Citations: 101     Fields:    Translation:HumansCTClinical Trials
  75. Mukohara, T. and Jänne, P.A. . HER2 inhibition and Clinical Achievements. Targeted Therapies in Oncology, Informa Healthcare. 2007; 45-54.
  76. Patel, M.R., Jacobson, B.A., Dr, A., Frizelle, S.P., Jänne, P.A., Thumma, S.C., Whitson, B.A., Farassati, F., and Kratzke, R.A. Ras pathway activation in malignant mesothelioma. Journal of Thoracic Oncology. 2007; 9(2):789-785.
  77. Sequist, L.V., Joshi, V.A., Jänne, P.A., Muzikansky, A., Fidias, P., Meyerson, M., Haber, D.A., Kuherlapati, R., Johnson, B.E. and Lynch, T.J. . Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007; (12):90-98.
  78. Jackman, D.M. and Jänne, P.A. . Does erlotinib improve symptoms in patients with lung cancer?. Nat Clin Pract Oncol. 2007.
  79. Johnson, B.E., Jackman, D.M. and Jänne, P.A. . Rationale for a Phase I Trial of Erlotinib and the mTOR inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer. Clinical Cancer Research. 2007; (13):4628-4631.
  80. Toschi, L. Cappuzzo, F. and Jänne, P.A. . Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. Annals of Oncology. 2007; Supplement 9:150-155.
  81. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, Bonomi P. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8. PMID: 17114658.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  82. Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer. 2007 Feb; 55(2):187-94. PMID: 17092602.
    Citations: 4     Fields:    Translation:Humans
  83. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6049-55. PMID: 17062680.
    Citations: 48     Fields:    Translation:HumansCTClinical Trials
  84. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20. PMID: 16983123.
    Citations: 77     Fields:    Translation:Humans
  85. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706. PMID: 16906227.
    Citations: 168     Fields:    Translation:HumansAnimalsCells
  86. Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s. PMID: 16857812.
    Citations: 17     Fields:    Translation:HumansAnimals
  87. Jänne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4416s-4420s. PMID: 16857820.
    Citations: 43     Fields:    Translation:HumansCells
  88. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006 Jul; 1(6):506-12. PMID: 17409909.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  89. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14. PMID: 16818686.
    Citations: 160     Fields:    Translation:Humans
  90. Allen AM, Czerminska M, Jänne PA, Sugarbaker DJ, Bueno R, Harris JR, Court L, Baldini EH. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006 Jul 01; 65(3):640-5. PMID: 16751058.
    Citations: 80     Fields:    Translation:Humans
  91. Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006 Jul; 12(7):852-5. PMID: 16799556.
    Citations: 112     Fields:    Translation:HumansCells
  92. Allen AM, Den R, Wong JS, Janne PA, Zurakowski D, Soto R, Bueno R, Sugarbaker DJ, Baldini EH. The influence of radiotherapy technique and dose on the patterns of failure for mesothelioma patients following extrapleural pneumonectomy. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7094. PMID: 27953361.
    Citations:    
  93. Janne PA, Paz-Ares Rodriguez L, Gottfried M, Reaume MN, Kaukel T, Oh YW, Sykes A, Enas N, Brail LH, Von Pawel J. Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7024. PMID: 27953240.
    Citations:    
  94. Simon GR, Janne PA, Langer C, Clarie V, Dowlati A, Gadgeel SM, Kelly K, Ye Z, Obasaju CK, Hood KE, Kindler HL. A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). J Clin Oncol. 2006 Jun 20; 24(18_suppl):2050. PMID: 27952676.
    Citations:    
  95. Ready N, Janne P, Herndon J, Bogart J, Crawford J, Edelman M, Wang X, Gu L, Green MR, Vokes EE. Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7046. PMID: 27953218.
    Citations:    
  96. Jackman DM, Yeap B, Lucca J, Ostler PA, Morse LK, Fidias P, Lynch TJ, Temel J, Johnson BE, Janne PA. Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7168. PMID: 27953799.
    Citations:    
  97. Borras AM, Kuang Y, Rogers AM, Holmes AJ, Gallegos Ruiz M, Joshi VA, Distel RJ, Giaccone G, Taron M, Janne PA. Detection of clinically significant mutations in the epidermal growth factor receptor missed by direct sequencing using a highly sensitive DNA endonuclease. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10054. PMID: 27954151.
    Citations:    
  98. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun; 9(6):485-95. PMID: 16730237.
    Citations: 147     Fields:    Translation:HumansAnimalsCells
  99. Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006 Apr 01; 24(10):1561-7. PMID: 16575008.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
  100. Sattler M, Walz C, Crowley BJ, Lengfelder E, Jänne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, Griffin JD. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood. 2006 Feb 01; 107(3):1237-8. PMID: 16434495.
    Citations: 3     Fields:    Translation:Humans
  101. Jänne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):751-8. PMID: 16467085.
    Citations: 62     Fields:    Translation:HumansCells
  102. Johnson B.E., Jackman, D., and Jänne P.A. . Impact of EGFR mutations on treatment of non-small cell lung cancer. . Cancer Chemother Pharmacol. 2006; Supplement 7(58):5-9.
  103. Jänne, P.A. Gefitinib for EGFR Mutant Lung Cancers: Searching for a Weapon of Mass Destruction. Journal of Clinical Oncology. 2006; 21(24):3319-3321.
  104. Sequist LV, Joshi VA, Jänne P.A., Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clinical Cancer Research. 2006; 14(12):4403s-4408s.
  105. Johnson BE and Jänne P.A. . Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer. Clinical Cancer Research. 2006; 14(12):4436s-4440s.
  106. Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne P.A., Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. . Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clinical Cancer Research. 2006; 14(12):4365s-4371s.
  107. Jänne P.A., Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clinical Cancer Research. 2006; 14(12):4416s-4420s.
  108. Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J.A., Jänne, P.A., Oulid-Alissa, D., and Soria, J.-C. . Erlotinib in front-line treatment of non-small cell lung cancer. A phase II study. Clinical Cancer Research. 2006; 20(12):6049-6055.
  109. Bruce Johnson, Pasi Jänne, Juan Paez, William Sellers, Matthew Meyerson. Method to Determine Responsiveness of Cancer to Epidermal Growth Factor Receptor Targeting Treatments (Pending). 2005.
  110. Jänne PA. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol. 2005 Dec; 32(6 Suppl 10):S9-15. PMID: 16459174.
    Citations: 3     Fields:    Translation:Humans
  111. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jänne PA. Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 2005 Nov 15; 11(22):8122-30. PMID: 16299245.
    Citations: 28     Fields:    Translation:HumansCells
  112. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313. PMID: 16187797.
    Citations: 211     Fields:    Translation:HumansAnimalsCells
  113. Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 01; 65(19):8968-74. PMID: 16204070.
    Citations: 52     Fields:    Translation:AnimalsCells
  114. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 01; 23(25):5900-9. PMID: 16043828.
    Citations: 416     Fields:    Translation:HumansCTClinical Trials
  115. Tsuchihashi Z, Khambata-Ford S, Hanna N, Jänne PA. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med. 2005 Jul 14; 353(2):208-9. PMID: 16014894.
    Citations: 29     Fields:    Translation:Humans
  116. Mukohara T, Civiello G, Johnson BE, Janne PA. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology. 2005; 68(4-6):500-10. PMID: 16020981.
    Citations: 5     Fields:    Translation:HumansCells
  117. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005 Jul; 7(1):40-6. PMID: 16098243.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  118. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005 Jul 01; 65(13):5561-70. PMID: 15994928.
    Citations: 129     Fields:    Translation:HumansCells
  119. Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EE. A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):7019. PMID: 27944450.
    Citations:    
  120. Lilenbaum R, Bonomi P, Ansari R, Lynch T, Govindan R, Janne P, Hanna N. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results. J Clin Oncol. 2005 Jun; 23(16_suppl):7036. PMID: 27944486.
    Citations:    
  121. Simon GR, Janne PA, Langer CJ, Verschraegen CF, Dowlati A, Gadgeel SM, Kelly K, Taylor L, Obasaju CK, Kindler HL. A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). J Clin Oncol. 2005 Jun; 23(16_suppl):7235. PMID: 27944730.
    Citations:    
  122. Jackman D, Lucca J, Fidias P, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Johnson BE, Janne PA. Phase II study of the EGFR tyrosine kinase erlotinib in patients = 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7148. PMID: 27944967.
    Citations:    
  123. Orlando M, Wozniak TF, Janne PA, Belani CP, Keohan ML, Ross HJ, Polikoff J, Mintzer DM, Ye Z, Obasaju CK. Survival update of a subset of previously treated patients with malignant pleural mesothelioma (MPM) in an expanded access program (eap) of pemetrexed (P) alone or combined with cisplatin (cis). J Clin Oncol. 2005 Jun; 23(16_suppl):7173. PMID: 27944995.
    Citations:    
  124. Bloss J, Wozniak TF, Janne PA, Belani CP, Keohan ML, Ross HJ, Polikoff J, Mintzer DM, Taylor L, Obasaju CK. Survival update on a subset of peritoneal mesothelioma (PM) patients in an expanded access program (EAP) of pemetrexed (P) alone or combined with cisplatin in the treatment of malignant mesothelioma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):7174. PMID: 27944990.
    Citations:    
  125. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005 May 10; 23(14):3227-34. PMID: 15886310.
    Citations: 93     Fields:    Translation:Humans
  126. Bruce Johnson, Pasi Jänne, Juan Paez, William Sellers, Matthew Meyerson . Method to Determine Responsiveness of Cancer to Epidermal Growth Factor Receptor Targeting Treatments (Pending). 2005.
  127. Mamon HJ, Yeap BY, Jänne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005 Mar 01; 23(7):1530-7. PMID: 15735128.
    Citations: 38     Fields:    Translation:Humans
  128. Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3788-93. PMID: 15731348.
    Citations: 164     Fields:    Translation:HumansAnimalsCells
  129. Kobayashi, S., Boggon, T.J., Dayaram, T., Jänne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Eck, M.J., Tenen, D.G., and Halmos, B. . Emergence of a drug resistance mutation in the epidermal growth factor receptor gene in gefitinib-responsive non small cell lung cancer. New England Journal of Medicine. 2005; (352):786-792.
  130. Johnson, B.E. and Jänne, P.A. . Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations?. Journal of Clinical Oncology. 2005; 28(23):6813-6816.
  131. Jackman, D.M., Chirieac, L., and Jänne, P.A. . Bronchioloalveolar Carcinoma: A Review of the Epidemiology, Pathology, and Treatment. Seminars in Respiratory and Critical Care Medicine. 2005; (26):342-352.
  132. Jänne, P.A. . Ongoing first line studies of epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) in select patient populations. Sem Oncol. 2005.
  133. Engelman, J.A. and Jänne, P.A. . Factors Predicting Response to EGFR Tyrosine Kinase Inhibitors. Seminars in Respiratory and Critical Care Medicine. 2005; (26):314-322.
  134. Jänne PA. [Gefitinib therapy in non-small-cell lung cancer]. Duodecim. 2005; 121(3):249-51. PMID: 15787283.
    Citations:    Fields:    Translation:Humans
  135. Johnson, B.E. and Jänne, P.A. . Tumor ablation for patients with lung cancer. Tumor Ablation: Principles and Practices. 2005; 459-465.
  136. Cho, D., Kocher, O., Lee, J.C., Tenen, D.G., Meyerson, M., Jänne, P.A. and Halmos, B. . Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer:case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small cell lung cancer. Journal of Clinical Oncology. 2005; 1(23):235-237.
  137. Mukohara, T., Engelman, J.A., Hanna, N.H., Yeap, B.Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L.C., Tenen, D.G., Johnson, B.E. and Jänne, P.A. . Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers. J Natl Cancer Inst. 2005; (97):1185-1194.
  138. Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. J Clin Oncol. 2005 Jan 01; 23(1):235-7. PMID: 15625379.
    Citations: 2     Fields:    Translation:Humans
  139. Jänne, P.A. . Targeted therapy for targeted patients. Why gefitinib is not effective in all patients with non-small cell lung cancer. Duodecim (in Finnish). 2005; 3(121):249-251.
  140. Johnson, B.E. and Jänne, P.A. . EGFR mutations in patients with non-small cell lung cancer. Cancer Research. 2005; (65):7525-7529.
  141. Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004 Nov; 14(4):567-73. PMID: 15559064.
    Citations: 10     Fields:    Translation:Humans
  142. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004 Oct 15; 64(20):7241-4. PMID: 15492241.
    Citations: 98     Fields:    Translation:HumansCells
  143. Mamon HJ, Yeap B, Reblando J, Shrager S, Jaklitsch MT, Lukanich JM, Sugarbaker DJ, Baldini E, Janne P, Bueno R. High risk of brain metastases in surgically staged IIIA NSCLC patients treated with surgery, chemotherapy and radiation. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7173. PMID: 28014275.
    Citations:    
  144. Bloss J, Wozniak A, Janne P, Belani C, Keohan M, Ross H, Polikoff J, Mintzer D, Bloss L, Obasaju C. Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):7198. PMID: 28014304.
    Citations:    
  145. Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, Janne PA, Hanna N. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):7084. PMID: 28016130.
    Citations:    
  146. Orlando M, Wozniak A, Janne P, Belani CP, Keohan ML, Ross H, Polikoff J, Mintzer D, Bloss L, Obasaju C. Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP). J Clin Oncol. 2004 Jul 15; 22(14_suppl):7195. PMID: 28014307.
    Citations:    
  147. Wozniak AJ, Janne P, Belani CP, Keohan ML, Ross H, Polikoff J, Mintzer D, Obasaju C. Pemetrexed in combination with cisplatin in the treatment of chemonaive patients with malignant pleural mesothelioma (MPM): Outcomes on Expanded Access Program (EAP). J Clin Oncol. 2004 Jul 15; 22(14_suppl):7192. PMID: 28014312.
    Citations:    
  148. Janne PA, Obasaju C, Simon G, Taub R, Kelly K, Fidias P, Bloss LP, Kindler HL. A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):7053. PMID: 28016122.
    Citations:    
  149. Johnson BE, Lucca J, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Liu G, Janne PA. Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7080. PMID: 28016134.
    Citations:    
  150. Zhao X, Li C, Paez JG, Chin K, Jänne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004 May 01; 64(9):3060-71. PMID: 15126342.
    Citations: 181     Fields:    Translation:Humans
  151. Wirth LJ, Carter MR, Jänne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004 May; 44(2):213-20. PMID: 15084386.
    Citations: 14     Fields:    Translation:Humans
  152. Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004 May; 44(2):221-30. PMID: 15084387.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  153. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500. PMID: 15118125.
    Citations: 2457     Fields:    Translation:HumansCells
  154. Jänne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, Meyerson M. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene. 2004 Apr 08; 23(15):2716-26. PMID: 15048096.
    Citations: 28     Fields:    Translation:HumansCells
  155. Johnson, B.E. and Jänne, P.A. . Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematology Oncology Clinics of North America. 2004; (18):309-322.
  156. Jänne, P.A., Engelman, J.A. and Johnson, B.E. . EGFR Mutations in Non-Small Cell Lung Cancer: Implications for treatment and tumor biology. Journal of Clinical Oncology. 2004; 14(23):3227-3234.
  157. Jänne, P.A. and Baldini, E.H. . Patterns of failure following surgical resection for malignant pleural mesothelioma. Thoracic Surgery Clinics. 2004; 4(14):567-573.
  158. Jänne, P.A. . First line chemotherapy for malignant mesothelioma. Mesothelioma. 2004.
  159. Janne PA. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer. 2003 Sep; 5(2):98-106. PMID: 14596692.
    Citations: 10     Fields:    Translation:Humans
  160. Libert Y, Janne P, Razavi D, Merckaert I, Scalliet P, Delvaux N, Etienne AM, Conradt S, Klastersky J, Boniver J, Reynaert C. Impact of medical specialists' locus of control on communication skills in oncological interviews. Br J Cancer. 2003 Feb 24; 88(4):502-9. PMID: 12592362.
    Citations: 3     Fields:    Translation:Humans
  161. Jänne PA. The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma. Ann Med. 2003; 35(7):450-7. PMID: 14649327.
    Citations:    Fields:    Translation:Humans
  162. Means-Markwell, M., Linnoila, R.I., Williams, J., Jänne, P.A., Kaye, F., O’Neil, K, and Johnson, B.E. . Prospective Study of Fluorescence Bronchoscopy of the Airways of Patients at Risk for Second Lung Cancer. Clinical Cancer Research. 2003; (9):5915-5921.
  163. Jänne, P.A. and Skarin, A.T. . Concurrent Docetaxel and Thoracic Radiation in Non-Small Cell Lung Cancer. Clinical Lung Cancer. 2003; (3):37-41.
  164. Wirth, L.J., Lucca, J., Ostler, P., Fidias, P., Lynch, C., Jänne, P.A., Herbst, R.S., Johnson, B.E., Sugarbaker, D.J., Mathisen, D.J., Lukanich, J.M., Choi, N.C., Berman, S.M. and Skarin, A.T. Phase I Study of Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer. Clincal Cancer Research. 2003; (9):1698-1704.
  165. Jänne, P.A. . The role of epidermal growth factor receptor in advanced non-small cell lung cancer. Annals of Medicine. 2003; 7(35):450-457.
  166. Jänne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7. PMID: 12234991.
    Citations: 25     Fields:    Translation:HumansCells
  167. Jänne PA, Skarin AT. Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S37-41. PMID: 14720346.
    Citations:    Fields:    
  168. Jeter, M.D, *Jänne, P.A, Brooks, S., Burstein, H.J., Wen, P., Fuchs, C., Loeffler, J.S., Devlin, P.M., and Salgia, R. . Gemcitabine-Induced Radiation Recall. Int J Radiat Oncol Biol Phys. 2002; 2(53):394-400.
  169. Jänne, P.A., Freidlin, B., Saxman, S., Johnson, D.H., Livingston, R.B., Shepherd, F.A., and Johnson, B.E. . Twenty Five Years of Clinical Research for Patients with Limited Stage Small Cell Lung Cancer in North America: Meaningful Improvements in Survival. Cancer. 2002; 7(95):1528-1538.
  170. Jänne, P.A., Taffaro, M.L., Salgia, R., and Johnson, B.E. . Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma. Cancer Research. 2002; (62):5242-5247.
  171. Hellsten, E., Evans, J.P, Bernard, D.J., Jänne, P.A., and Nussbaum, R.L. . Disrupted sperm function and fertilin ƒÒ processing in mice deficient in the inositol polyphosphate-5-phosphatase Inpp5b. Developmental Biology. 2001; (240):641-653.
  172. Jänne, P.A., Rodriguez-Thompson, D., Metcalf, D.R., Swanson, S.J., Greisman, H.A., Wilkins-Haug, L., and Johnson, B.E. . Chemotherapy for a Patient with Advanced Non-Small Cell Lung Cancer During Pregnancy: A Case Report and a Review of Chemotherapy Treatment During Pregnancy. Oncology. 2001; 3(61):175-183.
  173. Reynaert C, Libert Y, Janne P. ["Psychogenesis" of cancer: between myths, misuses and reality]. Bull Cancer. 2000 Sep; 87(9):655-64. PMID: 11038415.
    Citations: 1     Fields:    Translation:HumansAnimals
  174. Jänne, P.A. and Johnson, B.E. . The Role of MYC, JUN and FOS Oncogenes in Human Lung Cancer. In Pass, H.I., Mitchell, J.B., Johnson, D.H., Turrisi, A.T. and Minna, J.D., editors. Lung Cancer: Principles and Practice. 2000; 98-119.
  175. Jänne, P.A., Janicek, M.J. and Brown, F. Meningeal Carcinomatosis in Lung Cancer. Journal of Clinical Oncology. 2000; 18:2927-2929.
  176. Jänne, P.A. and Mayer R.J. Chemoprevention of Colorectal Cancer. New England Journal of Medicine. 2000; (342):1960-1968.
  177. Jänne, P.A., Datta, M.S., and Johnson, B.E. . Acrometastasis as an Initial Presentation of Non-Small Cell Lung Carcinoma. Journal of Clinical Oncology. 1999; 17:2998.
  178. Jänne, P.A., Suchy, S.F., Bernard, D., MacDonald, M., Crawley, J., Grinberg, A., Westphal, H., and Nussbaum, R.L. . Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL-1 does not cause Lowe syndrome in mice. Journal of Clinical Investigation. 1998; (101):2042-2053.
  179. Nussbaum, R.L., Orrison, B.M., Jänne, P.A., Charnas, L., and Chinault, A.C. . Physical mapping and genomic structure of the Lowe syndrome gene OCRL1. Human Genetics. 1997; (99):145-150.
  180. Danoff, T.M., Chiang, M., Jänne, P.A., and Neilson, E.G. . Screening for homologous recombination in ES cells using RT-PCR. Biotechniques. 1997; (22):22-24.
  181. Reynaert C, Janne P, Bosly A, Staquet P, Zdanowicz N, Vause M, Chatelain B, Lejeune D. From health locus of control to immune control: internal locus of control has a buffering effect on natural killer cell activity decrease in major depression. Acta Psychiatr Scand. 1995 Oct; 92(4):294-300. PMID: 8848955.
    Citations: 4     Fields:    Translation:HumansCells
  182. Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology (Berl). 1995 Mar; 118(2):183-7. PMID: 7617806.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  183. Olivos-Glander, I.M., Jänne, P.A., and Nussbaum, R.L. . The oculocerebrorenal syndrome gene product is a 105 kDa protein localized to the Golgi complex. American Journal of Human Genetics. 1995; (57):817-823.
  184. Reynaert C, Janne P, Delire V, Pirard M, Randour P, Collard E, Installé E, Coche E, Cassiers L. To control or to be controlled? From health locus of control to morphine control during patient-controlled analgesia. Psychother Psychosom. 1995; 64(2):74-81. PMID: 8559956.
    Citations: 2     Fields:    Translation:Humans
  185. Jänne, P.A., Rochelle, J.M., Martin-DeLeon, P.A., Stambolian, D., Seldin, M.F. and Nussbaum, R.L. . Mapping of the 75 kDa inositol polyphosphate-5-phosphatase (Inpp5b) to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens. Genomics. 1995; (28):280-285.
  186. Jänne, P.A., Dutra, A.S., Dracopoli, N.C., Charnas, L.C., Puck, J.M. and Nussbaum, R.L. Localization of the 75-kDa inositol polyphosphate-5-phosphatase (INPP5B) to human chromosome 1p34. Cytogenet Cell Genet. 1994; (66):164-166.
  187. Merry, D.E., Jänne, P.A., Landers, J.L., Lewis, R.A., and Nussbaum, R.L. . Isolation of a candidate gene for choroideremia. Proc Natl Acad Sci USA. 1992; (89):2135-2139.
  188. Harju, L., Jänne, P.A., Kallio, A., Laukkanen, M.-J., Lautenschlager, I., Mauttinen, S., Ranki, A., Soares, V.R.X., Söderlund, H., and Syvänen, A.C. Affinity-based collection of viral DNA: application to the detection of human immunodeficiency virus type 1, human cytomegalovirus and human papilomavirus type 16. Mol. Cell Probes. 1990; (4):223-235.
  189. Huang, L.-S., Jänne, P.A., de Graaf, J., Cooper, M., Decklebaum, R.J., Kayden, H., and Breslow, J.L. . Exclusion of linkage between the human apolipoprotein B gene and abetalipoproteinemia. American Journal of Human Genetics. 1990; (46):1141-1148.
  190. Hickok N, Seppänen PJ, Kontula KK, Jänne PA, Bardin CW, Jänne OA. . Two ornithine decarboxylase mRNA species in mouse kidney arise from size heterogeneity at their 3’ termini. Proc Natl Acad Sci USA. 1986; (83):594-598.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Janne's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (424)
Explore
_
Co-Authors (146)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.